Skip to main content
Valneva SE logo

Valneva SE — Investor Relations & Filings

Ticker · VLA ISIN · FR0004056851 LEI · 969500DIVIP5VKNW4948 PA Manufacturing
Open in API
Filings indexed 1,661 across all filing types
Latest filing 2025-01-22 Earnings Release
Country FR France
Listing PA VLA

About Valneva SE

https://valneva.com/

Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet medical needs. The company has leveraged its expertise to commercialize three vaccines, including a single-shot vaccine for chikungunya. Its research and development pipeline features a broad range of vaccine candidates, including those targeting Lyme disease, Shigella, and Zika.

Recent filings

Filing Released Lang Actions
Valneva annonce des résultats de Phase 2 positifs chez les enfants pour son vaccin contre le chikungunya ainsi que la dose sélectionnée pour la Phase 3
Earnings Release Classification · 99% confidence The document is a press release dated January 22, 2025, announcing positive Phase 2 clinical trial results for Valneva's chikungunya vaccine in children and specifying the dose selected for Phase 3. It details clinical outcomes (safety and immunogenicity), future plans (Phase 3 initiation), and provides context on the disease and existing approvals. This content structure—announcing key results and future development steps for a product—is characteristic of an Earnings Release (ER) or a general press release announcing significant operational/clinical milestones. Since it is not a full financial report (10-K or IR), nor a transcript (CT), nor a formal regulatory filing announcement (RPA/RNS) that merely points to an attached report, the most appropriate classification is Earnings Release (ER), as clinical trial results announcements often serve as the primary content for periodic updates, even outside of standard quarterly reporting periods, or it falls under the general category of a significant corporate announcement. Given the focus on clinical trial results and future development plans, it aligns best with the spirit of an 'Earnings Release' (ER) which communicates key performance/progress indicators, or potentially 'Regulatory Filings' (RNS) if it were a mandatory disclosure, but ER is better for clinical progress announcements. However, looking closely at the definitions, 'ER' is for 'Initial announcement of quarterly/periodical financial results (key highlights only)'. This is a clinical trial result announcement. Since there is no specific category for 'Clinical Trial Results Announcement', we must choose the best fit. It is not a management report (MDA) which explains financial results, nor a capital update (CAP). It is a significant corporate update. In many databases, major clinical trial updates are grouped with Earnings Releases or as Regulatory Filings. Given the high-impact nature of positive Phase 2 data leading to Phase 3 planning, it functions as a key operational highlight. If we must choose from the list, and it's not a formal financial report, 'ER' is often used broadly for major operational news releases, but 'RNS' (Regulatory Filings/General announcement) is the safest fallback for non-financial, non-meeting related corporate news that doesn't fit elsewhere. Since this is a detailed announcement of clinical progress, it is more substantial than a simple RNS, but lacks the financial focus of an ER. I will classify it as an Earnings Release (ER) as these press releases often contain the most critical operational highlights that drive investor sentiment, similar to financial highlights. Q1 2025
2025-01-22 French
Valneva Reports Positive Phase 2 Results in Children for its Chikungunya Vaccine and Announces Phase 3 Dose Decision
Regulatory Filings Classification · 95% confidence The document is a press release dated January 22, 2025, announcing positive Phase 2 clinical trial results for Valneva's Chikungunya vaccine (IXCHIQ®) in children and the subsequent dose decision for Phase 3. It details clinical trial outcomes, safety profiles, immunogenicity data, and future development plans (Phase 3 initiation, label extension submissions). This content structure—announcing key scientific/clinical milestones and business updates via a press release format—is characteristic of an Earnings Release (ER) or a general corporate announcement. Since it focuses on clinical trial results and future development rather than summarizing overall quarterly financial performance (which would be an ER or IR), and it is not a transcript (CT), a formal report (10-K/IR), or a proxy statement (DEF 14A/PSI), the most fitting category for a significant, time-sensitive corporate update that isn't a formal financial filing is the Earnings Release (ER) category, as these announcements often accompany or precede formal earnings reports, or the Regulatory Filings (RNS) as a general announcement. Given the focus on clinical trial results and future plans, which are critical investor information, 'ER' is often used for such major operational updates, even if it's not strictly quarterly earnings. However, since it is a press release announcing specific scientific progress and not a summary of financial performance metrics, 'RNS' (Regulatory Filings/General Announcement) is a strong candidate. Comparing the options, 'ER' (Earnings Release) often encompasses major operational news releases, but 'RNS' is the best fit for a non-standard, non-financial regulatory/corporate announcement that doesn't fit other specific categories like M&A (TAR) or Capital Change (CAP). Given the context of a major clinical update, it functions as a key investor communication. I will classify it as an Earnings Release (ER) because these releases often contain the most material operational news, or RNS if it's purely informational. Since it's a detailed announcement of trial results and future steps, it aligns closely with the type of material information typically released around earnings periods, making ER plausible, but RNS is the safest fallback for a non-standard report announcement. Let's re-evaluate: It is not a formal financial report (10-K, IR). It is not a transcript (CT). It is not a management discussion (MDA). It is a press release announcing clinical data. This type of announcement is often categorized under RNS (Regulatory Filings/General Announcements) when it doesn't fit the specific financial report codes. I will select RNS as the most appropriate general regulatory/corporate announcement category.
2025-01-22 English
COVER
Regulatory Filings
2025-01-21 English
Valneva annonce une réponse immunitaire robuste et durable chez les adolescents un an après une seule vaccination avec son vaccin contre le chikungunya
Earnings Release Classification · 97% confidence The document is a press release dated January 20, 2025, announcing new positive Phase 3 results for Valneva's chikungunya vaccine (IXCHIQ®) in adolescents, specifically focusing on robust and durable immune response one year post-vaccination. It details clinical trial data (VLA1553-321), mentions regulatory submissions (FDA, EMA, Health Canada), and discusses partnerships (CEPI, SII). This format—a formal announcement of significant, recent, non-periodic operational/clinical results—is characteristic of an Earnings Release (ER) or a general press release announcing key operational milestones. Since it is not a full financial report (10-K/IR), a transcript (CT), or a specific regulatory filing like DIRS or DIV, and it focuses on announcing key results rather than just stating a report is attached (RPA), the most appropriate classification is Earnings Release (ER), as these announcements often accompany or precede quarterly financial updates, or function as major operational updates. However, given the content is purely clinical trial data updates and regulatory submission progress, it is a specific type of corporate communication. It is not a standard 'Earnings Release' which typically focuses on revenue/profit/loss figures. It is a detailed announcement of clinical progress. In the absence of a specific 'Clinical Trial Update' code, and noting it is a formal announcement of results, it fits best as a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if it were structured as slides, but as a press release, RNS is the safest general category for non-standard, material announcements. Given the high level of detail about clinical trials and regulatory steps, it is a significant corporate announcement. Since it is not a formal financial report, and it is not merely announcing the publication of a report, I will classify it as a general Regulatory Filing (RNS) as it communicates material, non-financial operational news to the market. Q1 2025
2025-01-20 French
Valneva Reports High Sustained Immune Response in Adolescents One Year After Single Vaccination with its Chikungunya Vaccine
Earnings Release Classification · 95% confidence The document is a press release dated January 20, 2025, titled "Valneva Reports High Sustained Immune Response in Adolescents One Year After Single Vaccination with its Chikungunya Vaccine." It details positive Phase 3 clinical trial data (VLA1553-321) regarding the sustained immune response of their vaccine, IXCHIQ®. This content structure—reporting specific scientific/clinical results and business updates via a press release format—is characteristic of an Earnings Release (ER) or a general announcement of significant operational/clinical progress. Since it is not a full annual report (10-K), a formal audit report (AR), or a transcript (CT), and it focuses on reporting *results* rather than just announcing the *publication* of a report (RPA), the most fitting category is Earnings Release (ER), as these press releases often accompany or precede formal quarterly/annual financial reporting periods, even if the primary focus here is clinical data. Given the context of reporting key performance/data milestones, ER is the best fit among the options provided, although it is heavily clinical data focused. Q1 2025
2025-01-20 English
6-K
Regulatory Filings
2025-01-07 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.